Showing results (401-410 of 554) with videos related to

Sort By:
Pageof 56
Nature Communications|December 11, 2024
AR alterations inform circulating tumor DNA detection in metastatic castration resistant prostate cancer patientsTodd P Knutson, Bin Luo, Anna Kobilka, et al.
The Oncologist|April 22, 2025
Inferred clonal hematopoiesis from tumor DNA sequencing among men with prostate cancer: correlation with somatic tumor alterations and outcomesYasaman Iranmanesh, Noha Omar, Arya Rasouli, et al.
Cancer|December 29, 2025
Molecular alteration profiles characterize intraductal carcinoma of the prostateHarshitha Dudipala, Shayan S Nazari, Isabela Werneck da Cunha, et al.
Journal of the National Cancer Institute|September 10, 2024
Pan-cancer genomic analysis reveals FOXA1 amplification is associated with adverse outcomes in non-small cell lung, prostate, and breast cancersAlexander G Goglia, Mohammed Alshalalfa, Anwar Khan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 12, 2026
Molecular Characterization of KLK2 RNA Expression in Prostate CancerRana R McKay, Shayan S Nazari, Andrew Elliott, et al.
Oncotarget|July 25, 2025
Dissecting the functional differences and clinical features of R-spondin family members in metastatic prostate cancerAiden Deacon, Ava Gustafson, Allison Makovec, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 13, 2016
Sequencing of Sipuleucel-T and Androgen Deprivation Therapy in Men with Hormone-Sensitive Biochemically Recurrent Prostate Cancer: A Phase II Randomized TrialEmmanuel S Antonarakis, Adam S Kibel, Evan Y Yu, et al.
European Journal of Cancer (Oxford, England : 1990)|December 31, 2020
Bipolar androgen therapy sensitizes castration-resistant prostate cancer to subsequent androgen receptor ablative therapyLaura A Sena, Hao Wang, Su J Lim ScM, et al.
Aging|September 13, 2020
Preclinical studies show using enzalutamide is less effective in docetaxel-pretreated than in docetaxel-naïve prostate cancer cellsChangyi Lin, Fu-Ju Chou, Jieyang Lu, et al.
Prostate Cancer and Prostatic Diseases|October 26, 2025
HLA class I expression shapes the tumor immune microenvironment and influences prognosis in prostate cancerPornlada Likasitwatanakul, Carissa Besonen, Alexander K Tsai, et al.
Pageof 56